- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04148742
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
June 10, 2021 updated by: Dizal Pharmaceuticals
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Non-Hodgkin B-cell Lymphoma
This study will treat patients with non-Hodgkin B-cell lymphoma who have relapsed from, refractory or intolerant to prior therapy.
This study will help understand what type of side effects may occur with the drug treatment.
It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
Study Overview
Detailed Description
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Non-Hodgkin B-cell Lymphoma.
This study includes dose escalation (Part A) and dose expansion (Part B).
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nanjing, China
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
-
Nanjing, China
- Jiangsu Province Hospital - Haematology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Aged at least 18 years old.
- Patients must be willing and able to participate in all required evaluations and procedures.
- Patients must be able to provide a signed written informed consent.
- With documented histologically confirmed diagnosis of CLL/SLL, MCL or MZL and have least 1 measurable site of disease. Subjects must have relapsed, or are refractory or intolerant to >= 2 lines of prior therapy, and without preferred alternative treatment as judged by investigator. For Part B, subjects should be either BTK inhibitor treatment naive or intolerant to prior BTK inhibitor within 6 months on treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Predicted life expectancy ≥ 12 weeks.
- Adequate organ system functions.
Exclusion criteria:
- Prior malignancy requires active treatment within 2 to 3 years.
- A life-threatening illness, medical condition or organ system dysfunction.
- Radiotherapy with a limited field of radiation for palliation within 1 week of the screening.
- Major surgery within 4 weeks before screening.
- Prior treatment with any onco-immunotherapy within 4 weeks before screening.
- Subjects require immediate cytoreduction.
- Any history of Richter's transformation.
- Central nervous system (CNS) involvement unless previous treated and asymptomatic.
- Requires anticoagulation therapy with Warfarin, heparin.
- Known history of human immunodeficiency virus (HIV); Positive Hepatitis B surface antigen (HbsAg) or positive HCV antibodies; any other uncontrolled active systemic infection.
- Any of the following cardiac criteria: (1) mean resting corrected QT interval (QTcF) > 470 msec obtained from 3 electrocardiograms (ECGs). (2) prior history of atrial fibrillation. (3) any factors that increase the risk of QTcF prolongation, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval
- History of stroke or intracranial haemorrhage.
- Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection.
- History of hypersensitivity.
- Receiving (or unable to stop using) medications or herbal supplements known to be potent inhibitors or inducers of CYP3A.
- Grapefruit, grapefruit juice, and orange marmalade (made with Seville oranges) should be excluded.
- Women who are pregnant or breast feeding
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements
- Previous allogenic bone marrow transplant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: daily dose of DZD9008
|
Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated.
Starting dose of DZD9008 is 50 mg once daily.
If tolerated, subsequent cohorts will test increasing doses of DZD9008.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: Incidence of Treatment-Emergent Adverse Events
Time Frame: Through study completion, an average of 1.5 years
|
Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0
|
Through study completion, an average of 1.5 years
|
Part B: objective response rate (ORR)
Time Frame: Through study completion, an average of 1.5 years
|
Through study completion, an average of 1.5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum Plasma DZD9008 concentration
Time Frame: up to 16 weeks
|
up to 16 weeks
|
Plasma DZD9008 concentration- Area Under the Curve
Time Frame: up to 16 weeks
|
up to 16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 1, 2021
Primary Completion (Anticipated)
July 1, 2023
Study Completion (Anticipated)
July 1, 2023
Study Registration Dates
First Submitted
October 28, 2019
First Submitted That Met QC Criteria
October 30, 2019
First Posted (Actual)
November 1, 2019
Study Record Updates
Last Update Posted (Actual)
June 11, 2021
Last Update Submitted That Met QC Criteria
June 10, 2021
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DZ2019B0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's B-cell Lymphoma
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's LymphomaUnited States
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Debiopharm International SACompletedDiffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's LymphomaUnited States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland
-
Eden BioCell Ltd.National Taiwan University HospitalTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryTaiwan
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Not yet recruitingB-cell Non-Hodgkin's Lymphoma
-
Second Affiliated Hospital, School of Medicine,...Zhejiang Ruijiamei Biotechnologies, Co., Ltd.RecruitingB-cell Non-Hodgkin's LymphomaChina
-
Hutchison Medipharma LimitedRecruiting
-
Beijing Tsinghua Chang Gung HospitalChina Immunotech Pharmaceuticals Co.Ltd.Suspended
Clinical Trials on DZD9008
-
Dizal (Jiangsu) Pharmaceutical Co., Ltd.PPD Development, L.P.Recruiting
-
Peking Union Medical College HospitalDizal (Jiangsu) Pharmaceutical Co., Ltd.Recruiting
-
Dizal PharmaceuticalsCompletedHealthy VolunteersUnited States
-
Dizal PharmaceuticalsRecruitingNon-Small Cell Lung CancerSpain, Korea, Republic of, United States, Taiwan, France, Italy, Malaysia, Australia, Japan
-
Dizal PharmaceuticalsActive, not recruitingNon-Small Cell Lung CancerChina
-
Dizal PharmaceuticalsCompleted
-
Dizal PharmaceuticalsRecruiting
-
Dizal PharmaceuticalsRecruitingNon-small Cell Lung CancerChina
-
Dizal PharmaceuticalsRecruitingNon-small Cell Lung CancerChina
-
Dizal PharmaceuticalsCompletedHealthy SubjectsUnited States